跳转至内容
Merck
所有图片(4)

文件

461350

Sigma-Aldrich

1-Boc-4-哌啶酮

98%

别名:

N-Boc-4-哌啶酮, 叔丁基4-氧代-1-哌啶羧酸盐

登录查看公司和协议定价
所有图片(4)

About This Item

经验公式（希尔记法）:
C10H17NO3
CAS号:
79099-07-3
分子量:
199.25
Beilstein:
3650236
MDL號碼:
MFCD00151800
分類程式碼代碼:
12352100
PubChem物質ID:
24869846
NACRES:
NA.22

化驗

98%

mp

73-77 °C (lit.)

SMILES 字串

CC(C)(C)OC(=O)N1CCC(=O)CC1

InChI

1S/C10H17NO3/c1-10(2,3)14-9(13)11-6-4-8(12)5-7-11/h4-7H2,1-3H3

InChI 密鑰

ROUYFJUVMYHXFJ-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

1-Boc-4-哌啶酮在合成药物中被用作前体，同时也是合成选择性配体的合成砌块。

應用

1-Boc-4-哌啶酮，一个制药结构单元，可用于合成（3E，5E）-3,5-双（2,5-二甲氧基亚苄基）-1-叔丁氧基羰基哌啶-4-酮（RL197）。它也可以用于合成含有哌啶环结构的螺吡霉素。

警告

避免接触金属。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 2

1 of 2

四氢吡喃酮 99%

Sigma-Aldrich

198242

四氢吡喃酮

2,3-二氨基吡啶 95%

Sigma-Aldrich

125857

2,3-二氨基吡啶

In Ho Kim et al.
Bioorganic & medicinal chemistry letters, 17(5), 1181-1184 (2006-12-27)
A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series
Gebhard Thoma et al.
Journal of medicinal chemistry, 47(8), 1939-1955 (2004-04-02)
The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of
John W Clader et al.
Bioorganic & medicinal chemistry, 12(2), 319-326 (2004-01-16)
Anthranilamide analogues such as 23 are potent and highly selective muscarinic M2 antagonists that also show good oral bioavailability and in vivo activity.
Design, synthesis, and structure--activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors
Kamata, Makoto and Yamashita
Bioorganic & Medicinal Chemistry Letters, 22, 3643-3647 (2012)
Marlon Cowart et al.
Journal of medicinal chemistry, 47(15), 3853-3864 (2004-07-09)
A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门